| Identification | Back Directory | [Name]
BN201 | [CAS]
1361200-34-1 | [Synonyms]
BN201
BN-201,BN201
Glycinamide, N-[2-(2-fluorophenyl)ethyl]glycyl-N-(2-methylpropyl)glycyl-N2-[3-(2-oxo-1-pyrrolidinyl)propyl]- | [Molecular Formula]
C25H38FN5O4 | [MDL Number]
MFCD32664432 | [MOL File]
1361200-34-1.mol | [Molecular Weight]
491.6 |
| Hazard Information | Back Directory | [Uses]
BN201 promotes neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes (EC50 of 6.3 μM) in vitro, and the myelination of new axons (EC50 of 16.6 μM). BN201 is able to cross the blood-brain barrier by active transport and activate pathways (IGF-1 pathway) associated with the response to stress and neuron survival. BN201 has potently neuroprotective effects[1]. | [in vivo]
BN201 (12.5-150 mg/kg; intraperitoneal injection; daily; for 30 days; female C57BL/6 mice) treatment displays less axonal loss and neuron loss in both the spinal cord and in the optic nerve than the animals that received placebo[1]. | Animal Model: | Female C57BL/6 mice (8-12 weeks old) by immunization with MOG35-55 (experimental autoimmune encephalitis , EAE)[1] | | Dosage: | 12.5 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg, 150 mg/kg | | Administration: | Intraperitoneal injection; daily; for 30 days | | Result: | Displayed less axonal loss and neuron loss in both the spinal cord and in the optic nerve than the animals that received placebo.
|
| [References]
[1] Villoslada P, et al. Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation. Neurotherapeutics. 2019 Jul;16(3):808-827. DOI:10.1007/s13311-019-00717-4 |
|
| Company Name: |
ChemOrigin Pharm
|
| Telephone: |
15026428026 19002516454 |
| Website: |
www.chemorigin.com |
|